- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant, Granisetron, dexamethasone, Placebo
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
- Interventions
- palonesetron
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
- Interventions
- GW679769, Dexamethasone, Ondansetron Hydrochloride
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Oral GW679769, IV Cyclophosphamide 500-700mg/m2
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Newark, Delaware • Albuquerque, New Mexico • The Bronx, New York
- Conditions
- Nausea, Vomiting
- Interventions
- Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years to 87 Years
- Enrollment
- 942 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Downey, California • Riverside, California + 4 more
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- granisetron transdermal system, Granisetron IV
- Drug
- Lead sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 8 more
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Intranasal granisetron
- Drug
- Lead sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- The Study Is Managed by Kendle International, in Wilmington, North Carolina